Home・Aandelen Lijst・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Gesloten

SectorGezondheidszorg

59.29 0.88

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

58.66

Max

59.32

Belangrijke statistieken
By Trading Economics
Inkomsten	-34M 106M
Verkoop	-108M 766M
K/W Sectorgemiddelde	42.833 62.58
EPS	0.76
Winstmarge	13.773
Werknemers	3,221
EBITDA	177M 173M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+45.93% upside

Dividenden
By Acuity
Volgende Winsten	3 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1B 11B
Vorige openingsprijs	58.41
Vorige sluitingsprijs	59.29

Nieuwssentiment

By Acuity

50%

163 / 340 Rangschikking in Healthcare

BioMarin Pharmaceutical Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 15:46 UTC

Biomarin Pharmaceutical shares are higher today, reflecting a broader market rebound amid a significant decline in oil prices.

22 jul 2026, 23:31 UTC

Biomarin Pharmaceutical shares traded roughly flat in after-market hours amid rising crude oil prices and geopolitical tensions affecting market sentiment.

21 jul 2026, 15:36 UTC

Biomarin Pharmaceutical Inc shares are higher as the Nasdaq gains, supported by strong technology stocks. The stock trades above its 20-day moving average.

20 jul 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, remaining above their 20-day moving average amid broader market concerns over interest rates and economic growth.

16 jul 2026, 19:06 UTC

Macro Event

News

Citi analyst raises price target on Biomarin Pharmaceutical to $76.00, maintaining a Buy rating. Shares are higher today amid positive sentiment and notable volatility.

15 jul 2026, 23:21 UTC

Biomarin Pharmaceutical shares are higher in after-market trading, nearing the upper end of their one-month range amid broader market concerns over geopolitical tensions.

14 jul 2026, 19:31 UTC

Event

Biomarin Pharmaceutical shares are lower today, tracking declines in the Biotechnology sub-sector, continuing a downward trend since Monday's close.

13 jul 2026, 19:46 UTC

News

Event

BioMarin Pharmaceutical's supplemental New Drug Application for VOXZOGO has been accepted by the FDA. Shares are lower today amid broader market sentiment.

10 jul 2026, 23:46 UTC

Biomarin Pharmaceutical shares are lower in after-market trading, retracing from earlier highs. No specific news was identified to explain the movement.

9 jul 2026, 19:16 UTC

Biomarin Pharmaceutical Inc. shares are trading roughly flat with no specific news identified. The stock remains above its 20-day moving average.

8 jul 2026, 23:46 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting routine trading activity with minimal fluctuations and positioning above the 20-day moving average.

7 jul 2026, 23:32 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market trading, reflecting routine activity despite broader market volatility following Samsung Electronics' disappointing news.

6 jul 2026, 20:06 UTC

Biomarin Pharmaceutical shares are lower today, continuing a decline since Thursday. No specific news was identified to explain the trading activity.

2 jul 2026, 22:51 UTC

Biomarin Pharmaceutical Inc. shares were roughly flat in after-market trading, with no specific news identified. The stock has shown little change since Thursday's close.

1 jul 2026, 19:36 UTC

Biomarin Pharmaceutical Inc's shares are higher today, reaching a notable intraday high amid broader market caution and no specific company news identified.

30 jun 2026, 23:51 UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

29 jun 2026, 23:21 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, retracing from earlier gains amid mixed U.S. equity performance and broader inflation concerns.

26 jun 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25 jun 2026, 23:31 UTC

Biomarin Pharmaceutical shares declined in after-market trading, despite remaining above the 20-day moving average and near the upper end of its one-month range.

24 jun 2026, 19:41 UTC

Biomarin Pharmaceutical Inc is gaining Wednesday, supported by strong momentum in the Biotechnology sub-sector, despite an earlier decline in the session.

23 jun 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. Broader market sentiment is affected by declines in Asian markets amid tech sector concerns.

22 jun 2026, 23:56 UTC

Biomarin Pharmaceutical shares showed little change in after-market trading. The stock remains within the middle of its one-month trading range.

19 jun 2026, 00:01 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market hours, recovering from earlier lows and reflecting strong performance since Thursday's close.

18 jun 2026, 23:21 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close despite earlier fluctuations in the session.

17 jun 2026, 20:08 UTC

Event

Biomarin Pharmaceutical is trading lower amid broader market declines, despite presenting new data on VOXZOGO® and BMN 333 at the ENDO 2026 conference.

16 jun 2026, 23:41 UTC

Event

Biomarin Pharmaceutical presented new data on investigational therapies at the Endocrine Society Annual Meeting. Shares showed little change during after-market hours.

15 jun 2026, 13:26 UTC

Biomarin Pharmaceutical Inc is trading higher in pre-market hours, reflecting positive momentum amid a broader upward trend in Asian markets, including a surge in the Nikkei Index.

13 jun 2026, 00:01 UTC

Biomarin Pharmaceutical Inc shares declined in after-market trading, retracing from earlier gains while remaining above the 20-day moving average. No specific news was identified.

12 jun 2026, 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

11 jun 2026, 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, reaching an early session low. Broader economic news includes an unexpected rise in initial jobless claims.

Peer Vergelijking

Prijswijziging

BioMarin Pharmaceutical Inc Prognose

Koersdoel

By TipRanks

45.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 86.58 USD 45.93%

Hoogste 120 USD

Laagste 50 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioMarin Pharmaceutical Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Gebaseerd op 20 analisten die aandelenratings hebben gegeven aan BioMarin Pharmaceutical Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

163 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.